BASEL, Switzerland, July 24 --
- Not For US Media
- Set to Become First Medicine in EU to Treat Patients Aged Four and Older
Suffering From Life-Long Cryopyrin-Associated Periodic Syndrome (CAPS)(1)
- Ilaris Targets Interleukin-1 Beta (IL-1 Beta), a key Driver of
Inflammation(1,2,3) - Studies Ongoing in Other Diseases Involving IL-1 Beta Such
as Gout, COPD and Type 2 Diabetes
- EU Opinion Follows US and Swiss Approvals Based on Data Showing Ilaris
Produced Rapid and Sustained Remission in CAPS Patients After one Dose(2)
- CAPS Comprises Three Disorders of Increasing Severity With Potentially Fatal
Complications(2,3) - Most Patients Suffer From Severe and Disabling
Symptoms(1,3)